ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03389321
Recruitment Status : Completed
First Posted : January 3, 2018
Last Update Posted : February 8, 2018
Sponsor:
Information provided by (Responsible Party):
Actelion

Brief Summary:
Both macitentan and riociguat are indicated in the treatment of pulmonary arterial hypertension (PAH) and may be administered concomitantly. The primary objective of this study is to evaluate the effect of macitentan administered for 11 days on the pharmacokinetics (PK) (i.e., amount and time of presence in the blood of riociguat) of a single dose of riociguat in healthy male subjects.

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: Riociguat (Adempas) Drug: Macitentan (Opsumit) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Intervention Model Description: All the subjects included in the study will be included in a single group and will receive the drugs according to the same sequence
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of Macitentan at Steady State on the Pharmacokinetics of Riociguat in Healthy Male Subjects
Actual Study Start Date : January 9, 2018
Actual Primary Completion Date : February 6, 2018
Actual Study Completion Date : February 6, 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Treatment A-B
All subjects will receive treatment A followed by treatment B. Treatment A consists of a single oral dose (1 mg) of riociguat (Adempas) on Day 1. Treatment B consists of a loading oral dose of 30 mg macitentan (Opsumit) (3 tablets of 10 mg) on Day 5, then 10 mg of macitentan once daily from Day 6 to Day 15, with a concomitant administration of riociguat (1 mg) on Day 10.
Drug: Riociguat (Adempas)
Riociguat film-coated tablets for oral administration at a strength of 1 mg
Drug: Macitentan (Opsumit)
Macitentan film-coated tablets for oral administration at a strength of 10 mg
Other Name: ACT-064992



Primary Outcome Measures :
  1. Area under the plasma concentration-time curve (AUC) from zero to infinity [AUC(0-inf)] of riociguat [ Time Frame: Day 1 (pre-dose to 96 hours post-dose ), Day 10 (pre-dose to 144 hours post-dose) ]
    AUC(0-inf) of riociguat will be assessed following administration of riociguat alone or concomitantly with macitentan.

  2. Maximum plasma concentration (Cmax) of riociguat [ Time Frame: Day 1 (pre-dose to 96 hours post-dose ), Day 10 (pre-dose to 144 hours post-dose) ]
    The maximum observed plasma concentration of riociguat will be assessed following administration of riociguat alone or concomitantly with macitentan.


Secondary Outcome Measures :
  1. Time to reach Cmax (tmax) of riociguat and its metabolite M1 [ Time Frame: Day 1 (pre-dose to 96 hours post-dose ), Day 10 (pre-dose to 144 hours post-dose) ]
    The maximum observed time to reach Cmax of riociguat and M1 will be assessed following administration of riociguat alone or concomitantly with macitentan.

  2. Elimination half life (t1/2) of riociguat and its metabolite M1 [ Time Frame: Day 1 (pre-dose to 96 hours post-dose ), Day 10 (pre-dose to 144 hours post-dose) ]
    t1/2 of riociguat and M1 will be assessed following administration of riociguat alone or concomitantly with macitentan.

  3. AUC(0-t) of riociguat and its metabolite M1 [ Time Frame: Day 1 (pre-dose to 96 hours post-dose ), Day 10 (pre-dose to 144 hours post-dose) ]
    AUC(0-t) is the area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification. It will be determined for both riociguat and its metabolite M1 following administration of riociguat alone or concomitantly with macitentan.

  4. AUC(0-inf) of riociguat metabolite M1 [ Time Frame: Day 1 (pre-dose to 96 hours post-dose ), Day 10 (pre-dose to 144 hours post-dose) ]
    AUC(0-inf) of M1 will be assessed following administration of riociguat alone or concomitantly with macitentan.

  5. Maximum plasma concentration (Cmax) of riociguat metabolite M1 [ Time Frame: Day 1 (pre-dose to 96 hours post-dose ), Day 10 (pre-dose to 144 hours post-dose) ]
    The maximum observed plasma concentration of M1 will be assessed following administration of riociguat alone or concomitantly with macitentan.

  6. Trough concentration (Ctrough) of macitentan and its metabolite ACT-132577 [ Time Frame: Day 10 to Day 15 (before macitentan administration) and in the morning of Day 16 ]
    Ctrough of macitentan and its metabolite ACT-132577 will be assessed during the treatment period with macitentan (Day 10 to Day 15)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  • Male subjects aged between 18 and 45 years (inclusive) at screening who signed informed consent prior to any study-mandated procedure;
  • Healthy on the basis of physical examination, cardiac evaluations (12-lead ECG) and laboratory tests performed at screening;
  • Body mass index of 18 to 30 Kg/m2 (inclusive) at screening;
  • Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse rate 50-90 beats per minute (inclusive).

Key Exclusion Criteria:

  • Known allergic reactions or hypersensitivity to macitentan, riociguat, any drug of the same classes, or any of their excipients;
  • Any contraindication for riociguat treatment;
  • Known hypersensitivity or allergy to natural rubber latex;
  • Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions;
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion of the study treatments;
  • Previous treatment with any prescribed medications (including vaccines) or over the counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 3 weeks prior to first study treatment administration;
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

Other protocol defined inclusion and exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03389321


Locations
Germany
CRS Clinical Research Services Mannheim
Mannheim, Germany, 68167
Sponsors and Collaborators
Actelion
Investigators
Study Director: Shirin Bruderer, PhD Actelion

Responsible Party: Actelion
ClinicalTrials.gov Identifier: NCT03389321     History of Changes
Other Study ID Numbers: AC-055-123
2017-003502-41 ( EudraCT Number )
First Posted: January 3, 2018    Key Record Dates
Last Update Posted: February 8, 2018
Last Verified: February 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Actelion:
pharmacokinetics
macitentan
riociguat

Additional relevant MeSH terms:
Macitentan
Endothelin A Receptor Antagonists
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Endothelin B Receptor Antagonists